Back to top
more

Quest Diagnostics (DGX)

(Real Time Quote from BATS)

$154.44 USD

154.44
225,095

-0.85 (-0.55%)

Updated Nov 4, 2024 03:12 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 12% (29 out of 250)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Neogen (NEOG) Q4 Earnings Miss Estimates, Margins Crash

by Zacks Equity Research

Neogen's (NEOG) Food Safety and Animal Safety businesses witness a year-over-year decrease in revenues in the fourth quarter of fiscal 2024.

Integra's (IART) Q2 Earnings and Revenues Top, Margins Down

by Zacks Equity Research

Integra's (IART) second-quarter 2024 results reflect strong demand for its diverse portfolio of leading brands and the continued successful market adoption of CereLink.

Baxter's (BAX) Helion Surgical System Debuts in Thailand

by Zacks Equity Research

Baxter (BAX) launches the Helion Integrated Surgical System in Thailand, aiming to streamline operating room efficiency and enhance surgical team connectivity with cutting-edge technology.

DGX vs. PNTG: Which Stock Is the Better Value Option?

by Zacks Equity Research

DGX vs. PNTG: Which Stock Is the Better Value Option?

Hologic (HOLX) Q3 Earnings Surpass Estimates, Margins Rise

by Zacks Equity Research

Hologic (HOLX) delivers strong performances across all its franchises in the third quarter of fiscal 2024.

Avantor's (AVTR) Q2 Earnings Beat, Operating Margin Declines

by Zacks Equity Research

Avantor's (AVTR) revenues decline in the second quarter with new segmental changes. Bioprocessing orders decline. Operating margin contracts.

Are Investors Undervaluing Quest Diagnostics (DGX) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Integer Holdings (ITGR) Q2 Earnings Top Estimates, Margins Up

by Zacks Equity Research

Integer Holdings' (ITGR) second-quarter results reflect robust Medical Sales, along with strength in all the product lines.

DexCom's (DXCM) Q2 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

DexCom's (DXCM) second-quarter 2024 earnings surpass expectations while revenues fall short. The Sensor segment and CGM system expansion drive growth. Shares fall.

Hologic (HOLX) Buys Endomag to Boost Breast Cancer Solutions

by Zacks Equity Research

Hologic (HOLX) acquires Endomag for $310M, enhancing its breast cancer surgery portfolio with innovative technologies like Magseed and Magtrace, aiming to improve patient care and outcomes globally.

Amedisys (AMED) Q2 Earnings Top Estimates, Gross Margin Down

by Zacks Equity Research

Amedisys (AMED) delivers year-over-year growth in all three of its segmental revenues in the second quarter of 2024.

Terumo (TRUMY) Unit Reveals WEB 17 Device Effective in Aneurysms

by Zacks Equity Research

Terumo's (TRUMY) subsidiary MicroVention's WEB 17 device, used in treating intracranial aneurysms, demonstrates high safety and effectiveness in the CLEVER study.

Edwards Lifesciences (EW) Q2 Earnings Meet Mark, Margins Crash

by Zacks Equity Research

Edwards Lifesciences (EW) reports strong contributions from the TMTT product group in the second quarter of 2024.

Chemed (CHE) Q2 Earnings Miss Estimates, Margins Expand

by Zacks Equity Research

Chemed's (CHE) VITAS segment delivers impressive revenue growth and margin expansion in the second quarter of 2024.

AtriCure (ATRC) Gains China Approval for AtriClip LAA System

by Zacks Equity Research

AtriCure (ATRC) receives NMPA approval to market AtriClip Left Atrial Appendage Exclusion System in China, marking a significant step in global expansion.

Quest Diagnostics' (DGX) Haystack Oncology Forges New MRD Deal

by Zacks Equity Research

Quest Diagnostics' (DGX) subsidiary, Haystack Oncology, partners on the use of its MRD technology.

Cardinal Health's (CAH) China Syringe Makers Face FDA Warnings

by Zacks Equity Research

FDA investigations into Cardinal Health's (CAH) China-based syringe manufacturers, Jiangsu Shenli and Jiangsu Caina, reveal significant quality violations, prompting recalls and import alerts.

Quest Diagnostics (DGX) Tops Q2 Earnings, Raises 2024 Outlook

by Zacks Equity Research

Quest Diagnostics (DGX) delivers impressive base business growth in the second quarter of 2024.

Quest Diagnostics (DGX) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Quest Diagnostics (DGX) delivered earnings and revenue surprises of 1.73% and 0.50%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Patterson (PDCO) Expands AI Solutions in Canada via Alliance

by Zacks Equity Research

Patterson Companies (PDCO) unit and Pearl collaborate to bring advanced AI disease detection technology, Second Opinion, to Canada's dental practices, enhancing clinical performance and patient communication

Edwards Lifesciences (EW) Buys Innovalve to Boost TMVR Solutions

by Zacks Equity Research

Edwards Lifesciences (EW) exercises the option to acquire Innovalve Bio-Medical Ltd., strengthening its TMVR technology portfolio and addressing unmet needs in structural heart disease.

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

AMN Healthcare (AMN) Unveils ShiftWise Flex Manager Hub App

by Zacks Equity Research

AMN Healthcare's (AMN) Manager Hub app, part of the ShiftWise Flex platform, revolutionizes workforce management for healthcare organizations with enhanced mobile capabilities and comprehensive insights.

Here's Why Quest Diagnostics (DGX) is a Strong Value Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

BD (BDX) Up on Efforts to Tackle Blood Culture Vial Shortage

by Zacks Equity Research

BD (BDX) faces a shortage of blood culture vials due to supplier issues. It is ramping up production and collaborating with the FDA to ensure patient care remains unaffected.